01:4-1		]
Slide 1	Influenza - Pandemic on the Doorstep  Dr. Theresa Tam  Immunization and Respiratory Infections Division  Sponsored by:  3M Canada www.mmm.com  Hosted by: Paul Webber paul@webbertraining.com  www.webbertraining.com	
Slide 2	Objectives	
	Participants will achieve a basic understanding of:  The biological properties of the influenza virus and why it has the potential to cause pandemics  What a pandemic is, why it is a global health emergency, what happened in the past and why advanced planning is necessary now	
	Participants will gain an awareness of:  What preparedness and planning activities are occurring at international, national, regional and local levels  What components should be considered in a comprehensive plan  Strategies that have been used in preparation activities and the development of pandemic plans in Canada  Lessons learned from the SARS experience in Canada	
Slide 3		
	Influence views	
	Influenza virus  The Pandemic "Agent"	
	The rangemic Agent	

Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

C1		A	_	1
, <b>7</b> 1	П	ิด		4

# Influenza Virus: orthomyxoviridae · RNA virus, 8 segments mutate or recombine resulting in new viral · Lipid membrane contains -two spike glycoproteins: haemagglutinin & neuraminidase ABC of Influenza Virus · Influenza A (avian, humans, swine, equine, marine mammals) - 15 hemagglutinin subtypes - current human strains • H1N1 (H1N2) • H3N2 • Influenza B (humans) • Influenza C (humans, swine)

#### Slide 6

Slide 5

#### Antigenic Shift and Drift

Antigenic drift: a gradual change in the hemagglutinin and/or the neuraminidase proteins when the virus goes through a series of minor mutations and evolves over time (Influenza A & B)

Antigenic shift: an abrupt and major change in the hemagglutinin and/or the neuraminidase proteins resulting in the sudden appearance of a new influenza virus subtype (Influenza A)

### Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

Slide 7

Pandemic Influenza How Does It Occur?	_
Type A Type B	_
Annual Flu  Antigenic shift	_
	_
Novel virus No resistance	_
Human to human transmission Illnesses and death	_

~1		1	റ
~	11.	പപ	v
וכי	ш	de	8

#### Pandemic Influenza

What is it?

Why plan for it?

What can be done to prepare for it?



#### Slide 9

What is an Influenza Pandemic?

- A sudden, widespread outbreak of a new strain of influenza
- · Virtually no one is immune
- Virus is capable of efficient human to human transmission, resulting in large amount of illness and death

Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com


Slide 10

Pandemic Influenza History					
<ul> <li>Spanish Flu 1918</li> <li>Asian Flu 1957</li> <li>Hong Kong Flu 1968</li> </ul> Pandemic scares: <ul> <li>Swine Flu 1976</li> <li>Hong Kong Avian Flu 1997 and 2003</li> </ul>	FRED CIESON DIED DIE TENTEN ACTUAL TREE AC				

Slide 11

#### Each Pandemic is Different Year Interval(yrs) Subtype Severity 1889 H3N2 moderate H1N1 1918 29 severe H2N2 1957 39 severe 1968 11 H3N2 moderate H1N1

Slide 12




Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

$\alpha$	٠.	1	- 1	
<b>√</b>	1.	പച	- 1	-4
O.	ш	de	_ 1	J


Pandemic Influenza What We Know and the Uncertainties

- Another influenza pandemic is INEVITABLE
- Timing and epidemiology UNPREDICTABLE
- SHORT LEAD TIME
  - presence in Canada within 3 months
  - $-\,$  1st peak in illness within 5-7 months
- Outbreaks will occur SIMULTANEOUSLY in multiple locations, in multiple waves

### Slide 14




### Slide 15




<b>Hosted by Paul Webber</b>	paul@webbertraining.com
A Webber Tr	aining Teleclass
www.webbe	rtraining.com

Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com


Slide 16



Slide 17



Slide 18



Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

<b>U</b>	140	
וכי	lide	19

Worldwide Spread of Asian Influenza Pandemic	_
September 1957	
	_
<i>Λ</i>	

### Slide 20

#### Influenza Pandemic: Then and Now

- · Increase in world population and changing demographics (e.g. immunocompromised hosts)
- · Jets may spread the disease very rapidly in hours or
- · In developed countries
  - Improved medical care, antibiotics for secondary infections
  - Vaccines and antivirals for prophylaxis
  - Antiviral drugs for treatment

### Slide 21

#### Recent Experience with Avian Influenza


- 1997 H5N1 in Hong Kong
  - 18 cases and 6 deaths
     Mass culling of poultry
  - International demand for antiviral drugs
- 2003
  - H5N1 in China/Hong Kong
  - Two confirmed human infections with one fatality
     H7N7 in the Netherlands

  - One death and more than 80 cases of mild disease (mainly conjunctivitis) in humans associated with affected poultry farms
  - Family members of ill poultry workers also had mild respiratory disease suggesting possible human to human spread


<b>Hosted by Paul Webber</b>	paul@webbertraining.com
A Webber Tr	aining Teleclass
www.webbe	rtraining.com

Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

Slide 22



Slide 23



Slide 24



Slide 25	, , , , , , , , , , , , , , , , , , ,	]
Silue 23		
	Preparedness Activities:	
	International	
		1
Slide 26		1
Silde 26	Global Agenda for Influenza Surveillance and	
	Control (WHO)	
	Major Themes     1.Improvement in the quality and coverage of virological and	
	epidemiological influenza surveillance	
	<ol><li>Improvement in the understanding of health and economic burden of influenza, including benefits from epidemic control</li></ol>	
	and pandemic preparedness  3. Expansion in the use of existing vaccines, particularly in	
	developing countries and in high-risk groups and acceleration in the introduction of new vaccines	
	4.Increase in national and global epidemic and pandemic	
	preparedness, including vaccine and pharmaceutical supplies	
C1: 1 27		1
Slide 27	Global Influenza Surveillance Network	
	Global influenza Sal ventalice i vetwork	
	Virological surveillance     110 national influenza	
	laboratories  1 lab/country	
	■ >1 lab/country - • 4 regional reference	
	centres	
	❖WHO, Global Agenda: May 2002	
	to expand the existing laboratory surveillance network and	
	increase disease surveillance for influenza control and pandemic preparedness.	

$\alpha$	•	1		_	_
S	•	~	$\sim$	′,	v
. 7	ш	ш	_		$^{\sim}$

Silue 28	Rationale for strengthening international	
	influenza surveillance	
	Surveillance of human, wild and domestic animal populations in high	
	risk areas is key to:	
	<ul> <li>vaccine development</li> <li>development of an early warning system for viruses with</li> </ul>	
	pandemic potential	
	areas where	
	birds, pigs and humans live in	
	close proximity are high risk	
	environments for antigenic drift	
	and shift.	
~	_	•
Slide 29	World Health Organization (WHO)	
	Pandemic Phases	
	Phase 0, Level 0 - Inter-Pandemic period	
	Phase 0, Level 1 - Novel virus identification in a human	
	Phase 0, Level 2 - Human infection confirmed     Phase 0, Level 3 - Human-to-Human Transmission Confirmed	
	Phase 1 - Pandemic confirmed	
	Phase 2 - Outbreaks in multiple geographic areas     Phase 3 - End of first wave	
	Phase 4 - Second or later waves	
	Phase 5 - Post-Pandemic / Recovery	
Slide 30		
	Preparedness Activities:	
	r repareuness Activities.	
	National	
	1	

### Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

	Sponsored by 3M Canad	a www.mmm.com
Slide 31	National Level Activities  Development of pandemic plans Approximately 30 countries worldwide now have a plan for pandemic influenza Use of the WHO Pandemic Phases improves communication and consistency Requires national coordination and agreement on goals of pandemic preparedness and response  National surveillance for influenza-like illness and influenza viruses Vaccine strategies Development of Stockpiles / Antiviral strategy	
Slide 32	Pandemic Planning Activities In Canada	
Slide 33	Overall Goal of Pandemic Preparedness and Response	

Hosted by Paul Webber paul@webbertraining.com A Webber Training Teleclass www.webbertraining.com

First, to minimize serious illness and overall deaths, and second to minimize societal societal disruption among Canadians as a result of an influenza

### Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

Slide 34

Dandamic	Preparedness	Milactonec


- 1988 1st draft plan
- 1996 2<sup>nd</sup> draft plan
- 1997 lessons learnt from Hong Kong "Bird flu"
- · 1998 to 2002
  - Federal/Provincial/Territorial Working Agreement (Mar. 2001)
     Established security of vaccine supply with pandemic vaccine contract (Sep. 2001)
  - Pandemic Influenza Committee (PIC) established (Mar. 2002)
- 2003 Canadian Pandemic Influenza Plan, to be realigned with other public health emergency plans and revised in light of SARS experience

Slide 35

#### Pandemic Influenza Committee Working Groups

- · Surveillance and Laboratory Testing
- Vaccines
- Antivirals
- Health Services
  - Resource Management
- Non-Traditional Sites and Workers
- Mass fatalities
- Clinical Care
- Infection Control
- · Public Health Measures
- · Communication

Slide 36




Slide 3/	Organization of the Canadian Pandemic	
	Influenza Plan	
	<ul> <li>Use of WHO pandemic phases terminology</li> <li>Preparedness and response activities organized by pandemic phase</li> </ul>	
	and components  Components of the Plan:	
	Surveillance	
	Vaccine Programs     Antivirals	
	Health Services     Emergency Services	
	Public Health Measures     Communications	
	<ul> <li>Working groups to address each component and to developed specific guidelines/protocols</li> </ul>	
Slide 38		
onde 50	Surveillance	
	Strengthen current FluWatch surveillance system	
	Strengthen rational laboratory capacity	
	national laboratory standards, training workshop	
	- detection of all influenza subtypes	
	- antivirals resistance monitoring	
	Collaboration in international surveillance     WHO Global Agenda	
	- WHO GROUND AGENTA  http://www.who.int/emc/diseases/flu/global_agenda_repo rt/Introduction.htm	
		-
Slide 39		1
Silue 39	Vaccine Strategy	
	Vaccine strategy options and security of supply	
	<ul> <li>provide vaccines to all Canadians (75% uptake)</li> </ul>	
	domestic capacity and multiple suppliers     Guidelines on use in short supply	
	Guidelines on use in short supply     Strategies for delivery and administration in mass	
	campaigns	
	Monitoring of distribution, uptake, wastage     Vaccine adverse events surveillance	
	Vaccine adverse events surveillance     Vaccine clinical trials protocols	
	amount of antigen required, need for adjuvants	

### Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

$\alpha$	٠.	1		40
· ·	1 n.	А.	$\sim$	40
. 7		ш	_	41

				. ~	
Α	nt	11/	ıra	Strategy	7

- The only public health intervention prior to effective vaccine becoming available
- · Options for use and stockpiling
  - Amantadine for prophylaxis
  - Neuraminidase inhibitors for treatment
- · Guidelines on use of antivirals in short supply
- · Clinical guidelines
- · Monitoring for adverse events and resistance

- · No national stockpile at this time · Strategies for delivery, administration
- Monitoring of distribution, uptake, wastage

$\alpha$		1		4
~	1	പറ	· /I	
1	ш	de	4	

#### Infection Control Guidelines

- · Infection control in different settings
  - · hospitals
  - · triage sites (clinics and others)
  - · non-traditional health care sites (temporary hospitals or clinics)
  - self care
  - · corpse management

#### Slide 42

#### Clinical Guidelines

- · Patient assessment & management in different settings
  - triage of adult and paediatric patients with or without influenza-like illness
  - long term care facilities self sufficiency
- · Management in event of extreme shortage of resources - ethics


$\alpha$	٠.	1			
S	1 n.	~ 1	^	/	. 7
. 7			_	4	

Siluc 43		
	Resource Management	
	Guidelines for acute care facilities     beds: capacity, tracking, maximizing, prioritization     supplies: meds, equipment & supplies management	
	<ul> <li>health care workers - staff &amp; volunteers</li> <li>definitions</li> <li>deployment &amp; recruitment, training</li> </ul>	
	"conscription", compensation, liability insurance, licensing     counseling and support	
	Guidelines for corpse management	
	L	
Slide 44	Non-Traditional Sites and Workers	
	Identification & use of alternative care sites  – administrative options e.g. linked with acute care setting	
	<ul> <li>type of patient care delivery</li> <li>criteria for appropriate site</li> <li>resource requirements and insurance</li> </ul>	
	tools: equipment & medical supplies checklists  Identification, training & protection of non-traditional workers     roles and responsibilities and skill sets	
	sources of labour, recruitment, screening     insurance of employed and volunteer staff     tools: job descriptions and redeployment checklist, educational resources,	
	training guidelines	
Slide 45		1
Silue 45	Public Health Measures	
	Facilitating a consistent public health response to the management of pandemic influenza	
	Guideline document in development addressing:     Public Health management of cases and contacts	
	Use of quarantine and isolation Contact tracing for special circumstance e.g. Airplanes Travel advice and recommended restrictions	
	Recommendations for control through limitation/cancellation of large gatherings	

~1	•	1			-
S	•	~ 1	`	/	4
. •		116	-	4	

Slide 46	Emergency Response  Support Health Services Response and Maintain Essential Community Services  • pandemics are different from other emergencies  – communities must respond without outside assistance  – slower onset, prolonged course  – highly infectious disease  – reduction in human resources  • ensure close collaboration between public health and	
	emergency responders at all levels  • build on existing emergency response frameworks  • exercise the response plans	
Slide 47	Communication Strategy  Consistent and uniform messaging  framework  tools & vehicles  implementation plan education Canadian Coalition for Influenza Immunization annual campaign	
Slide 48	Preparedness Activities: Regional and Local Levels	

Presented by Dr. Theresa Tam Sponsored by 3M Canada www.mmm.com

	Sponsored by 3M Canad	a www.mmm.com
Slide 49	Strategies for Regional and Local Planning  Get all stakeholders involved Agree upon goals and objectives Divide and conquer Use existing expertise to develop documents relevant to their setting Consolidate and re-assess Incorporate lessons learned from other experiences that have "challenged" the system or facility Test and evaluate plan and revise as necessary Ongoing education of stakeholders, potential partners and public	
Slide 50	Within Canada  Most Provinces and Territories have developed plans for pandemic influenza  Some provinces and territories are at the stage where they are testing their plans  Local level planning is occurring  Post-SARS high level of recognition for need for plans to mitigate the impact of pandemic influenza	
Slide 51		
	Lessons Learned from the SARS Experience in	

Hosted by Paul Webber paul@webbertraining.com A Webber Training Teleclass www.webbertraining.com

Canada

~1		1		_	-
Sl	•	~ ~	•	4	2
. 7	ш		-	•	/

Silue 32		
	Lessons Learned: General	
	Team work is essential	
	<ul> <li>Plan for dedicated team leadership that will not be pulled away to deal with other arising issues</li> </ul>	
	<ul> <li>Plan staffing to allow for time off but for continuity of response activities (e.g. rotating shifts)</li> </ul>	
	*	
	Strengthen human resource planning and surge capacity in emergency plans	
	District the second sec	
	<ul> <li>Plan to support your staff/responders</li> <li>Meals, off-hours transportation, family responsibilities</li> </ul>	
G1: 1 50		1
Slide 53	Lessons Learned: General	
	<ul> <li>Need to strengthen communicable disease emergency response plans and use common approaches for different</li> </ul>	
	infectious agents  • Need to have a "think tank" team that is not directly involved	
	in the minute by minute response	
	Response team components     Coordination and Operations (with international liaison)	
	Technical (surveillance, epidemiology, public health guidelines etc.)	
	- Logistics	
	<ul><li>Communications</li><li>Think Tank</li></ul>	
		•
C1: 1 - <i>E</i> 4	Г	1
Slide 54	Lessons Learned: Disease Control	
	Quarantine/isolation generally acceptable to the public as in controlling SARS but need for support systems	
	Cancellation of public gatherings will happen	
	regardless of public health recommendations	
	<ul> <li>Involve partners in implementation of public health measures (education, information dissemination)</li> </ul>	
	Blood and border issues will arise quickly	
		<u>-</u>

<b>~</b>	1	М	$\alpha$	4	4
S1	ш	u	<b>C</b>	. )	

Silue 33		
	Lessons Learned: Surveillance	
	Strengthen and coordinate hospital and public health	
	surveillance systems to detect emerging respiratory infections of significance	
	Establish case definition early with rationale and be consistent with highest level organization if at all possible	
	Establish minimum dataset and data sharing agreements at the	
	outset for emerging infectious diseases  Establish mechanism and processes for alerting public health	
	and health care providers in real time	
Slide 56		]
Silde 30	Lessons Learned: Communication	
	Pre-established internal and national networks worked; need to	
	strengthen international networks  • Establish communication systems that permit optimal use of	
	all participants time  - decide who needs to know everything immediately and	
	who does not	
	<ul> <li>Human resources to translate science (particularly epidemiology) into public information</li> </ul>	
	Real-time, evidence-based communications practice     be pro-active rather than reactive	
	Perception IS reality	
		1
Slide 57	Lessons Learned: Infection Surveillance and	
	Control in Acute Care Settings	
	Lack of trained personnel especially in non-tertiary care settings	
	Varying capacity for surveillance and need to	
	coordinate with public health  Impact of intensive SARS infection control measures	
	for prolonged periods:  - Health care worker well-being	
	Increase in other nosocomial infections e.g. MRSA	

Slide 58	Questions ?	
G1: 1 - 50		•
Slide 59	References	
	WHO website on Global Agenda for Influenza Surveillance and Control <a href="http://www.who.int/csr/disease/influenza/globalagenda/en/">http://www.who.int/csr/disease/influenza/globalagenda/en/&gt;</a>	
	<ul> <li>Health Canada: FluWatch and SARS         <a href="http://www.he-sc.gc.ca/">http://www.he-sc.gc.ca/</a> </li> <li>Special Issue: Influenza Vaccine Vaccine Volume 21</li> </ul>	
	<ul><li>(16) 1 May 2003.</li><li>"The State of Infection Surveillance and Control in Canadian Acute Care Hospitals"</li></ul>	
	- Zoutman et al., AJIC, August 2003	